WO1994005319A1 - Composition adjuvante des fonctions cerebrales, renforçateur de capacite d'apprentissage, agent mnemonique, preventif et curatif de la demence, ou nutriment fonctionnel adjuvant des fonctions cerebrales - Google Patents

Composition adjuvante des fonctions cerebrales, renforçateur de capacite d'apprentissage, agent mnemonique, preventif et curatif de la demence, ou nutriment fonctionnel adjuvant des fonctions cerebrales Download PDF

Info

Publication number
WO1994005319A1
WO1994005319A1 PCT/JP1992/001626 JP9201626W WO9405319A1 WO 1994005319 A1 WO1994005319 A1 WO 1994005319A1 JP 9201626 W JP9201626 W JP 9201626W WO 9405319 A1 WO9405319 A1 WO 9405319A1
Authority
WO
WIPO (PCT)
Prior art keywords
brain function
dementia
composition
group
dha
Prior art date
Application number
PCT/JP1992/001626
Other languages
English (en)
Japanese (ja)
Inventor
Masazumi Nisikawa
Shoji Kimura
Kazuaki Maruyama
Original Assignee
Taiyo Gyogyo Kabusiki Kaisya
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiyo Gyogyo Kabusiki Kaisya filed Critical Taiyo Gyogyo Kabusiki Kaisya
Publication of WO1994005319A1 publication Critical patent/WO1994005319A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Definitions

  • Brain function improving composition learning ability enhancer, memory enhancer, dementia preventive agent, dementia therapeutic agent, or functional food having brain function improving effect
  • the present invention relates to a substance having an effect of improving brain function, that is, a brain function improving composition, and a learning ability enhancer, a memory enhancer, and a drug embodied using the brain function improving composition.
  • the present invention relates to a dementia preventive agent, a therapeutic agent for dementia, a functional food having an effect of improving brain function, and the like.
  • the methods of improving brain function that have been studied in the past include a method of improving brain energy metabolism that efficiently absorbs nutrients into brain cells and activates the function of the cells. It is broadly divided into cerebral circulation improvement methods that provide sufficient nutrients and oxygen necessary for brain cells, and research is progressing on drugs and treatments that have their respective pathological effects.
  • cerebral disorders include Alzheimer-type dementia caused by nervous system disorders and cerebrovascular dementia caused by cerebrovascular disorders. They seem to be recognized in two types, and it seems that research on drugs and treatments corresponding to each type is underway.
  • phosphatidylcholine which is a choline-containing phospholipid
  • acetylcholine is supplied to the brain, and thereby, Alzheimer-type dementia and other neurological disorders. Prevention and treatment of disability are expected.
  • phosphatidylethanolamine a kind of phospholipid, is converted to phosphatidylcholine by a methyl group transfer reaction from S-adenosylmethionine nin. Therefore, the phosphatidylethanolamine is also expected to be used as a preventive and therapeutic agent for Alzheimer's dementia and other neurological disorders.
  • Kisae phosphate to de co Sa is one of the active ingredients with brain function improving effect, C 22 1 1 32 0 2 , molecular weight 3 2 8.4 In g, it is a straight-chain hexanoic acid having 22 carbon atoms having a cis double bond at positions 4, 7, 10, 13, 16 and 19, and its melting point is 14.5. ⁇ 14.1 ° C.
  • alpha-linolenic a precursor of DHA
  • Symptoms were improved when linseed oil containing a large amount of acid (50 to 60%) was given, but it was described that the symptoms returned when the administration was stopped.
  • Examples of a memory enhancer and a therapeutic agent for senile dementia which have been recently announced include, for example, a memory enhancer comprising (1) 2- (7-indenyloxymethyl) morpholine or an acid addition salt thereof as an active ingredient.
  • a memory enhancer comprising (1) 2- (7-indenyloxymethyl) morpholine or an acid addition salt thereof as an active ingredient.
  • (2) Therapeutic treatment of Alzheimer's disease characterized by comprising a salt of dexoxamin to which a pharmaceutically acceptable acid is added Japanese Patent Application Laid-Open No.
  • the present invention responds to the above-mentioned demands, improves brain function, thereby enhancing learning ability, memory ability, preventing and treating senile dementia, and has a functional function that has a brain function improving effect. It does not embody food.
  • the present inventors have found that the physiological activity and drug activity of docosahexaenoic acid, which is abundantly contained in oils obtained from dinosaurs, sardines, etc., are unique to okiamis in marine animals. Studying the physiological and drug activities of phosphatides, which are widely contained in a variety of products, have shown that a mixture of these two materials has a strong learning ability in addition to animal test results. Have the effect of improving dementia and preventing and treating dementia. Is present as part of the constituents of plants in nature, and is extremely useful as a drug or food that has the effect of improving brain function because its safety has been confirmed empirically. Thus, the present invention has been completed.
  • the mixture when a mixture of a phospholipid and DHA, which is a precursor of acetylcholine which is a neurotransmitter in the brain, is administered to a rat, the mixture improves the learning ability. It has been found from experimental results that it is effective in improving the function, improving memory, and preventing and treating senile dementia.Thus, it is necessary to use these pharmacological effects to realize products such as drugs and foods. It was done.
  • rats fed and fed a feed containing docosahexaenoic acid-containing fats and oils and phospholipids as active ingredients were fed through the Y maze with the rats in the control area. It is used to conduct experiments to improve learning ability and memory ability.
  • a wister-based rat and a mixture of DHA ethyl ester and phospholipid were used as active ingredients.
  • the mixed feed and the Y maze were prepared, and the rat was put in the Y maze, and the following experiment was performed.
  • wister-type rats a total of 80 male Wistar-type 4-week-old rats were prepared and divided into four groups of 20 rats each. Depending on the type of feed fed for the period, the test group is group 4 and the control group is group 1.
  • the test feed divided into the test group 4 and the control group 1 was a feed mixed with the following components. That is, the formula feed used in the experiment is composed of raw materials having the mixing ratios shown in Tables 1A and 1B.
  • the composition of fats, which are the components, is as shown in Table 2. 4 types of test feed Try to use
  • Table 1 A Table 1A: Mixing ratio of each component in feed Case 20%
  • E test feed group 20 male 4-week-old rats were preliminarily reared for one week, and then were subjected to a test diet mixed with a mixture of ethyl ester and phospholipid containing DHA (E test diet in Table 2) for 1 week. Ward). After that, place the rats in individual cages so that the weight of the rat becomes 85% for 2 weeks, and carry out the Sham pinng before conducting this test.
  • E test feed group a group of rats reared on the E test feed.
  • the experimental method involves first placing the animal at the starting point. The animal then begins exploring and, after a while, reaches the selected location, where it chooses the side with the light and the bait or the side without the light and bait. Animals that were able to reach the bait side within 30 seconds of placing at the departure point were considered correct, and those that took longer and entered the bait side were incorrect. The animal only sees the light at the selected point in the Y maze, learns to be able to ingest food on the side of the light, and examines its memory by repeating it daily. .
  • Fig. 1 shows the response of the test diet group
  • Fig. 3 shows the response of the test diet group
  • Fig. 4 shows the response of the control diet group.At the beginning, all three groups prefer nocturnal properties. , R-(the number of incorrect responses) is higher than R + (the number of correct responses), but in the E test feed group, R — decreases from around day 5 and R- While the + increased significantly, the control diet group showed little decrease in R — and therefore the accuracy rate did not increase much.
  • the D test diet group containing only DHA-containing ethyl ester alone showed an intermediate increase in the correct answer rate. This means that the DHA ethyl ester group learns to get food if it goes to the light side earlier than the control group, and remembers it for many days. become. Furthermore, it was found that the effect was enhanced by adding a phospholipid to DHA ethyl ester.
  • T test feed group a rat group bred on the T test feed is referred to as a T test feed group.
  • mice 1 test in total, 100 experiments were performed 18 times per day 5 times / day for each animal in the T test diet group.
  • the experimental method involves first placing the animal at the starting point. Do the animals Begins an exploratory action and after a short time reaches the selected point, where he chooses the side with the light and the bait or the side without the light and bait. Animals that were able to reach the bait side within 30 seconds of placing at the departure point were considered correct, and those that took longer and entered the bait side were incorrect. The animal only sees the light at the selected point in the Y maze, learns to be able to ingest food on the side of the light, and repeats this daily to improve its memory. Find out.
  • the correct response rate of the T test diet group reached 78% on the 18th day after the start of the experiment, and the correct response rate of the control test diet group and the D test diet group. It showed extremely high normal reaction efficiency.
  • Fig. 6 shows the response of the T test diet group
  • Fig. 7 shows the response of the D test diet group
  • Fig. 8 shows the response of the control diet group.
  • R-(number of incorrect responses) is higher than R + (number of correct responses)
  • R — decreases and R While + significantly increased, R-did not decrease significantly in the control diet group, and therefore the accuracy rate did not increase much.
  • the D test diet group containing only DHA-containing ethyl ester alone showed an intermediate increase in the correct answer rate.
  • the DHA-containing group learns to get food if it goes to the light side earlier than the control feed group, and remembers it for many days. become. Furthermore, it was found that the effect was enhanced by adding phospholipids to DHA-containing triglycerides. From the above, it was found that (feed group mixed with triglyceride and phospholipid containing DHA) had a strong learning effect and memory ability in the light-dark discrimination feeding behavior performed using the Y maze. It was found to increase.
  • R test feed group After pre-breeding 20 male Wistar 4-week-old rats for 1 week, the test diet mixed with a mixture of DHA-containing phospholipids and DHA-containing ethyl ester (R in Table 2) (Test feed section). After that, the rats are placed in individual cages so that the weight of the rat becomes 85% for 2 weeks. In the following, the rats bred on the R test feed are referred to as (R test feed group).
  • the experimental method involves first placing the animal at the starting point. The animal then begins exploring and, after a while, reaches the selected location, where it chooses the side with the light and the bait or the side without the light and bait. Animals that were able to reach the bait side within 30 seconds of placing at the departure point were considered correct, and those that took longer and entered the bait side were incorrect. Animals only see the lights at the selected point in the Y maze, learn to be able to ingest food on the lighted side, and examine their memory by repeating this daily.
  • Fig. 10 shows the response of the R test diet group
  • Fig. 11 shows the response of the D test diet group
  • Fig. 12 shows the response of the control diet group.
  • R — (number of incorrect responses) is higher than R + (number of correct responses), but in the R test diet group, R — decreases from around day 5
  • the R + increased significantly
  • the control diet group showed little decrease in R —
  • the correct answer rate did not increase so much.
  • the D test diet group containing only DHA-containing ethyl ester alone showed an intermediate increase in the correct answer rate.
  • the DHA-containing group learns to get food if it goes to the light side earlier than the control diet group, and remembers it for many days. Become.
  • the docosahexaenoic acid used in the above-mentioned invention of the present application can be used as the acid itself, but is also an ethyl ester, a methyl ester, or a triglyceride, and is preferably Any lipid type such as phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylserine (PS), phosphatidylinositol (PI), etc. Is mentioned.
  • PC phosphatidylcholine
  • PE phosphatidylethanolamine
  • PS phosphatidylserine
  • PI phosphatidylinositol
  • lipophilic lipid used in the present invention those derived from soybean can be used as long as they are vegetable lipolids, and those derived from egg yolk or okiami can be used as vegetable lipolids.
  • Power preferably DHA This is an unused marine resource that contains a large amount of phospholipids, and includes phospholipids extracted from Okiami, which is rich in resources. However, since the DHA content of the okiami phospholipid is about 20%, it is more effective to supplement it with higher-purity DHA.
  • the mixture of DHA and phospholipid used in the present invention may have a phospholipid content of 0.1% or more, and more preferably, a phospholipid content of about 10%.
  • a daily dose of lmg to 100 g, preferably lmg to 10 g is recommended.
  • the docosahexaenoic acid and its mixture of phospholipids and phospholipids containing docosahexaenoic acid and ethyl ester, methyl ester, triglyceride, and docosahexaenoic acid according to the present invention are intact. It can be a learning-enhancing agent, a memory-enhancing agent, a therapeutic or prophylactic agent for dementia, but is pharmaceutically acceptable diluent and / or pharmacologically acceptable diluent and / or other according to pharmaceutical practice. It can also be formulated as a mixture with other pharmacologically active substances.
  • composition may be prepared in the form of tablets or packages in dosage units.
  • examples of such a form that can be taken as a medicament include powders, granules, tablets, dragees, capsules, pills, solutions, ampules, and injections.
  • Formulation means also include the sun contained in a mixture with a pharmaceutically acceptable diluent.
  • diluent include excipients, extenders, binders, wetting agents, disintegrants, surfactants, lubricants, dispersants, buffers, flavoring agents, flavoring agents, Perfumes, preservatives, dissolution-adjuvants, solvents, coatings, and the like are conceivable, but are not limited to these.
  • Formulation may be performed by any known method, for example, activity
  • the components can also be mixed with a diluent, formed into granules and then formed into a tablet to form the composition.
  • FIG. 1 is a graph showing the progress of acquisition (positive response rate%) of the Y maze light / dark discrimination food-feeding behavior experiment of Experimental Example 1 according to the present invention.
  • FIG. 2 is a graph showing the DHA-containing ethyl ester in Experimental Example 1 of the present invention.
  • Figure 3 shows the number of correct responses and incorrect responses in the DHA-containing ethyl ester group in Experimental Example 1.
  • FIG. 4 is a graph showing the number of correct responses and the number of incorrect responses in the control group in Example 1 of the experiment.
  • Fig. 5 is a graph showing the learning process (correct response rate%) of the bait-taking behavior in Y-maze light / dark discrimination in Experimental Example 2.
  • Fig. 6 shows the triglyceride containing DHA in Experimental Example 2.
  • Fig. 7 is a graph showing the number of correct responses and the number of incorrect responses in the group mixed with C and phospholipids.Fig. 7 shows the number of correct responses and the number of incorrect responses in the DHA-containing ester group in Experimental Example 2.
  • Fig. 8 is a graph showing the number of correct responses and the number of incorrect responses in the control group in Experimental Example 2.
  • Fig. 9 is a graph showing the learning process (correct response rate%) of the Y maze light / dark discrimination baiting behavior experiment in Experimental Example 3.
  • Fig. 10 is a graph showing the DHA-containing phospholipid group in Experimental Example 3.
  • Fig. 11 is a graph showing the number of correct responses and the number of incorrect responses.
  • Fig. 11 is a graph showing the number of correct responses and the incorrect response of the DHA-containing ethyl ester group in Example 3 of the experiment.
  • 4 is a graph showing the number of correct responses and the number of incorrect responses in the control group in Experimental Example 3.
  • the formulation was adjusted to a tablet formulation containing the components shown in Table 3.
  • the tablets were coated with sugar, the present invention is not limited to this, and it is a matter of course that the tablets may be coated with other suitable materials.
  • a hard capsule was obtained using the above-described untableted powder in a form formulation of 600 mg.
  • the purity of DHA used in the drug should be at least 50% in the total fatty acid composition, but preferably at least 90%. It is desirable that
  • the functional food which is a mixture of docosahexaenoic acid and phospholipid according to the present invention, may be an oil or fat containing 10% or more docosahexaenoic acid.
  • fats and oils containing 18% or more are desirable.
  • Margarine containing docosahexaenoic acid was prepared according to the formulation examples shown in Table 4.
  • Table 5 Example of mayonnaise containing docosahexaenoic acid Egg yolk (containing 20% phospholipids) 8.0% Salada oil 70.0%
  • composition of the emulsion was adjusted according to the formulation examples shown in Table 6. Table 6.
  • the first invention of the present application is intended to enhance a brain function or recover a brain disorder by a brain function improving composition containing a mixture of docosahexaenoic acid (DHA) and a phospholipid as an active ingredient.
  • DHA docosahexaenoic acid
  • a phospholipid as an active ingredient.
  • it can be commercialized as a raw material for drugs and functional foods, or it can be mixed with appropriate pharmacologically acceptable carriers, excipients, and diluents. It may be commercialized by processing it into a desired form such as a liquid, powder, granule, tablet, injection, capsule, suppository and the like. In addition, it may be administered orally in the form described above or parenterally. In addition, it goes without saying that the dosage may be increased or decreased depending on the age, weight, symptoms, etc., when administering the drug.
  • DHA docosahexaenoic acid
  • the present invention when a mixture of docosahexaenoic acid and phospholipid, which is a substance having an effect of improving brain function, is ingested into the human body in the form of a drug or food.
  • the learning ability is enhanced by the active ingredient, and the memory ability is enhanced.
  • the composition for improving brain function is prevented beforehand. It is effective in treating various types of dementia.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention vise à améliorer les fonctions cérébrales pour conférer un renforcement de la capacité d'apprentissage, de la capacité de mémorisation, et de la prévention et du traitement de la démence sénile et elle vise à fournir un nutriment fonctionnel à effet adjuvant des fonctions cérébrales. La composition inventée comprend au moins un élément choisi parmi des acides gras insaturés en n-3, c'est-à-dire acide docosahexénoïque, acide eicosapentaénoïque et acide α-linolénique en tant qu'ingrédient actif et, en plus, au moins un phospholipide choisi parmi phosphatidylcholine (PC), phosphatidyléthanolamine (PE), phosphatidylinositol (PI) et leurs dérivés lysés correspondants.
PCT/JP1992/001626 1992-09-02 1992-12-15 Composition adjuvante des fonctions cerebrales, renforçateur de capacite d'apprentissage, agent mnemonique, preventif et curatif de la demence, ou nutriment fonctionnel adjuvant des fonctions cerebrales WO1994005319A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP4/260713 1992-09-02
JP4260713A JPH0717855A (ja) 1992-09-02 1992-09-02 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤、痴呆治療剤、または脳機能改善効果を有する機能性食品

Publications (1)

Publication Number Publication Date
WO1994005319A1 true WO1994005319A1 (fr) 1994-03-17

Family

ID=17351728

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1992/001626 WO1994005319A1 (fr) 1992-09-02 1992-12-15 Composition adjuvante des fonctions cerebrales, renforçateur de capacite d'apprentissage, agent mnemonique, preventif et curatif de la demence, ou nutriment fonctionnel adjuvant des fonctions cerebrales

Country Status (2)

Country Link
JP (1) JPH0717855A (fr)
WO (1) WO1994005319A1 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2721516A1 (fr) * 1994-06-27 1995-12-29 Inst Rech Biolog Sa Nouvelles utilisations d'un complexe à base de phospholipides cérébraux en thérapeutique et dans l'alimentation.
US6117853A (en) * 1994-11-08 2000-09-12 Kabushiki Kaisha Yakult Honsha Cerebration improver
DE19943198A1 (de) * 1999-09-09 2001-03-15 Meyer Lucas Gmbh & Co Therapeutikum zur Behebung zentralnervöser Funktionsstörungen
US7888391B2 (en) 2001-11-14 2011-02-15 N.V. Nutricia Method for reducing the severity of neurological disorders
US8865687B2 (en) 2000-05-08 2014-10-21 N.V. Nutricia Preparation for the prevention and/or treatment of vascular disorders
US9132196B2 (en) 2007-12-20 2015-09-15 N. V. Nutricia Palatable nutritional composition comprising a nucleotide and/or a nucleoside and a taste masking agent
CN106819153A (zh) * 2015-12-04 2017-06-13 金士力佳友(天津)有限公司 一种含美藤果油和深海鱼油的调和油及其应用
CN111743996A (zh) * 2020-06-24 2020-10-09 上海互众药业有限公司 一种具有增加记忆力改善老年痴呆口服乳剂及其制作方法
US11395810B2 (en) 2007-06-26 2022-07-26 N.V. Nutricia Memory in subjects with mini-mental state examination of 24-26

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962488A (en) * 1998-04-08 1999-10-05 Roberts Laboratories, Inc. Stable pharmaceutical formulations for treating internal bowel syndrome containing isoxazole derivatives
JP4344039B2 (ja) * 1999-04-09 2009-10-14 株式会社ヤクルト本社 夢見促進剤
JP2003261456A (ja) * 2002-03-08 2003-09-16 Howaizu:Kk 脳の老化予防剤
DE10340740A1 (de) * 2003-09-04 2005-03-31 Degussa Food Ingredients Gmbh Physiologisch aktive Zusammensetzung auf Phosphatidylserin-Basis
JP4891522B2 (ja) * 2003-10-03 2012-03-07 株式会社ファンケル 血清ｇｏｔ、ｇｐｔ改善剤
IL158552A0 (en) * 2003-10-22 2004-05-12 Enzymotec Ltd Lipids containing omega-3 fatty acids
US8052992B2 (en) 2003-10-22 2011-11-08 Enzymotec Ltd. Glycerophospholipids containing omega-3 and omega-6 fatty acids and their use in the treatment and improvement of cognitive functions
JPWO2005046668A1 (ja) * 2003-11-14 2007-05-24 持田製薬株式会社 言語障害予防・治療剤
US20070122452A1 (en) * 2003-12-22 2007-05-31 Wakunaga Pharmaceuticla Co., Ltd Fat composition
JP2005263668A (ja) * 2004-03-17 2005-09-29 Nof Corp ホスファチジルセリン含有水性組成物及び用途
WO2006059397A1 (fr) * 2004-12-02 2006-06-08 Nippon Meat Packers, Inc. Aliment antistress
CN101443010A (zh) 2006-04-10 2009-05-27 三菱瓦斯化学株式会社 脑功能改善剂及含有该改善剂的功能性食品
EP2382978A3 (fr) * 2006-06-09 2012-01-18 Erasmus University Medical Center Rotterdam Modulation du système immunitaire par phospholipidiques d'inositol
US20100028465A1 (en) 2007-01-16 2010-02-04 Hiroyuki Fukami Composition for ameliorating cerebral function
JP6067558B2 (ja) 2011-06-29 2017-01-25 日本水産株式会社 恐怖記憶の軽減方法
JP6831558B2 (ja) * 2016-08-23 2021-02-17 株式会社Ｈｂｃフナト 脳機能改善組成物
WO2021039385A1 (fr) * 2019-08-28 2021-03-04 ユニテックフーズ株式会社 Composition orale pour améliorer la capacité d'apprentissage de mémorisation

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62111926A (ja) * 1985-11-11 1987-05-22 Nippon Oil & Fats Co Ltd コリン作働性神経系活性化剤
JPS6422819A (en) * 1987-06-24 1989-01-25 Efamol Ltd Amnesia treating or preventing composition
JPS6470439A (en) * 1987-05-28 1989-03-15 Innoba D Ridorufui Furoola E C Extraction of polyunsaturated fatty acid from fish oil and medicine and/or feed composition containing same ester
JPH01135720A (ja) * 1987-11-20 1989-05-29 Eisai Co Ltd 神経線維再生剤
JPH01279827A (ja) * 1988-05-02 1989-11-10 Taiyo Fishery Co Ltd 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤、痴呆治療剤、または脳機能改善効果を有する機能性食品
JPH01279830A (ja) * 1988-05-02 1989-11-10 Nippon Oil & Fats Co Ltd コリン作働性薬剤
JPH01290625A (ja) * 1988-05-16 1989-11-22 Nippon Oil & Fats Co Ltd 脳機能向上剤
JPH0249723A (ja) * 1988-04-18 1990-02-20 Taiyo Fishery Co Ltd 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤または痴呆治療剤
JPH02215351A (ja) * 1989-02-14 1990-08-28 Taiyo Fishery Co Ltd オキアミリン脂質の分取方法
JPH0358926A (ja) * 1989-07-27 1991-03-14 Taiyo Fishery Co Ltd 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤、痴呆治療剤、または脳機能改善効果を有する機能性食品
JPH0413626A (ja) * 1990-05-01 1992-01-17 Q P Corp 健脳組成物
JPH0488963A (ja) * 1990-08-02 1992-03-23 Sagami Chem Res Center 機能性健康食品及び飼料
JPH0494669A (ja) * 1990-08-08 1992-03-26 Q P Corp 脳機能改善用食品又は医薬品組成物並びにその製造方法

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62111926A (ja) * 1985-11-11 1987-05-22 Nippon Oil & Fats Co Ltd コリン作働性神経系活性化剤
JPS6470439A (en) * 1987-05-28 1989-03-15 Innoba D Ridorufui Furoola E C Extraction of polyunsaturated fatty acid from fish oil and medicine and/or feed composition containing same ester
JPS6422819A (en) * 1987-06-24 1989-01-25 Efamol Ltd Amnesia treating or preventing composition
JPH01135720A (ja) * 1987-11-20 1989-05-29 Eisai Co Ltd 神経線維再生剤
JPH0249723A (ja) * 1988-04-18 1990-02-20 Taiyo Fishery Co Ltd 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤または痴呆治療剤
JPH01279827A (ja) * 1988-05-02 1989-11-10 Taiyo Fishery Co Ltd 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤、痴呆治療剤、または脳機能改善効果を有する機能性食品
JPH01279830A (ja) * 1988-05-02 1989-11-10 Nippon Oil & Fats Co Ltd コリン作働性薬剤
JPH01290625A (ja) * 1988-05-16 1989-11-22 Nippon Oil & Fats Co Ltd 脳機能向上剤
JPH02215351A (ja) * 1989-02-14 1990-08-28 Taiyo Fishery Co Ltd オキアミリン脂質の分取方法
JPH0358926A (ja) * 1989-07-27 1991-03-14 Taiyo Fishery Co Ltd 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤、痴呆治療剤、または脳機能改善効果を有する機能性食品
JPH0413626A (ja) * 1990-05-01 1992-01-17 Q P Corp 健脳組成物
JPH0488963A (ja) * 1990-08-02 1992-03-23 Sagami Chem Res Center 機能性健康食品及び飼料
JPH0494669A (ja) * 1990-08-08 1992-03-26 Q P Corp 脳機能改善用食品又は医薬品組成物並びにその製造方法

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2721516A1 (fr) * 1994-06-27 1995-12-29 Inst Rech Biolog Sa Nouvelles utilisations d'un complexe à base de phospholipides cérébraux en thérapeutique et dans l'alimentation.
WO1996000077A1 (fr) * 1994-06-27 1996-01-04 Institut De Recherche Biologique Nouvelles utilisations d'un complexe a base de phospholipides cerebraux en therapeutique et dans l'alimentation
US6117853A (en) * 1994-11-08 2000-09-12 Kabushiki Kaisha Yakult Honsha Cerebration improver
DE19943198A1 (de) * 1999-09-09 2001-03-15 Meyer Lucas Gmbh & Co Therapeutikum zur Behebung zentralnervöser Funktionsstörungen
US8865687B2 (en) 2000-05-08 2014-10-21 N.V. Nutricia Preparation for the prevention and/or treatment of vascular disorders
US8362078B2 (en) 2001-11-14 2013-01-29 N.V. Nutricia Method for reducing the severity of neurological disorders
US7888391B2 (en) 2001-11-14 2011-02-15 N.V. Nutricia Method for reducing the severity of neurological disorders
US9504712B2 (en) 2001-11-14 2016-11-29 N.V. Nutricia Preparation for improving the action of receptors
US9844525B2 (en) 2001-11-14 2017-12-19 N.V. Nutricia Preparation for improving the action of receptors
US11395810B2 (en) 2007-06-26 2022-07-26 N.V. Nutricia Memory in subjects with mini-mental state examination of 24-26
US9132196B2 (en) 2007-12-20 2015-09-15 N. V. Nutricia Palatable nutritional composition comprising a nucleotide and/or a nucleoside and a taste masking agent
US9687555B2 (en) 2007-12-20 2017-06-27 N.V. Nutricia Palatable nutritional composition comprising a nucleotide and/or a nucleoside and a taste masking agent
CN106819153A (zh) * 2015-12-04 2017-06-13 金士力佳友(天津)有限公司 一种含美藤果油和深海鱼油的调和油及其应用
CN111743996A (zh) * 2020-06-24 2020-10-09 上海互众药业有限公司 一种具有增加记忆力改善老年痴呆口服乳剂及其制作方法

Also Published As

Publication number Publication date
JPH0717855A (ja) 1995-01-20

Similar Documents

Publication Publication Date Title
WO1994005319A1 (fr) Composition adjuvante des fonctions cerebrales, renforçateur de capacite d'apprentissage, agent mnemonique, preventif et curatif de la demence, ou nutriment fonctionnel adjuvant des fonctions cerebrales
KR100402040B1 (ko) 이성질체가 강화된 공액 리놀레산 조성물의 이용 방법
TWI285549B (en) Therapeutic combinations of fatty acids
JP2524217B2 (ja) 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤または痴呆治療剤
EP1166652B1 (fr) Utilisation d'une matiere contenant de l'acide docosapentaenoique
JP2003048831A (ja) 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
JPH044298B2 (fr)
US20020032233A1 (en) Methods of using isomer enriched conjugated linoleic acid compositions
EP0914108A1 (fr) Composition a base de pyruvate et de composes anti-cortisol, et procede permettant d'augmenter la concentration de proteines chez un mammifere
US20090099261A1 (en) Omega-3 mixtures
EP0769917B1 (fr) Compositions a base d'acide nervonique
EP0790056B1 (fr) Utilisation d' un agent preventif ou remede pour guerir des maladies provoquees par des anomalies dans les tissus cartilagineux
JPS63104917A (ja) コレステロール低下または上昇抑制剤
JPH0358926A (ja) 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤、痴呆治療剤、または脳機能改善効果を有する機能性食品
JP2941787B2 (ja) 多価不飽和脂肪酸を含有する医薬組成物および健康食品
AU711302C (en) Nervonic acid compositions
JPH11343236A (ja) 多価不飽和脂肪酸を含有する医薬組成物および健康食品
JP2002265360A (ja) 中性脂肪低減剤

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase